Developments in component therapy: novel components and new uses for familiar preparations.

Michelle S. Wright-Kanuth, Linda A. Smith

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified. The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products. In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include: donor leukocyte infusions, dendritic cell vaccines, blood substitutes, novel platelet products and substitutes, intravenous immunoglobulin (IVIG), fresh frozen plasma and cryosupernatant in therapeutic plasma exchange. The variety of products and conditions reflect the ever-expanding role of immunohematology in the treatment of disease.

Original languageEnglish (US)
Pages (from-to)116-124
Number of pages9
JournalClinical laboratory science : journal of the American Society for Medical Technology
Volume15
Issue number2
StatePublished - Mar 2002
Externally publishedYes

Fingerprint

Blood Substitutes
Blood
Erythrocytes
Plasmas
Blood Platelets
Platelets
Blood Component Removal
Plasma Exchange
Intravenous Immunoglobulins
Dendritic Cells
Chemotherapy
Communicable Diseases
Immune system
Immune System
Leukocytes
Therapeutics
Vaccines
Ablation
Bone Marrow
Tissue Donors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Developments in component therapy : novel components and new uses for familiar preparations. / Wright-Kanuth, Michelle S.; Smith, Linda A.

In: Clinical laboratory science : journal of the American Society for Medical Technology, Vol. 15, No. 2, 03.2002, p. 116-124.

Research output: Contribution to journalArticle

@article{81ac83d417e640bb9484373119407bd5,
title = "Developments in component therapy: novel components and new uses for familiar preparations.",
abstract = "Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified. The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products. In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include: donor leukocyte infusions, dendritic cell vaccines, blood substitutes, novel platelet products and substitutes, intravenous immunoglobulin (IVIG), fresh frozen plasma and cryosupernatant in therapeutic plasma exchange. The variety of products and conditions reflect the ever-expanding role of immunohematology in the treatment of disease.",
author = "Wright-Kanuth, {Michelle S.} and Smith, {Linda A.}",
year = "2002",
month = "3",
language = "English (US)",
volume = "15",
pages = "116--124",
journal = "Journal of Medical Technology",
issn = "0894-959X",
publisher = "American Society for Clinical Laboratory Science",
number = "2",

}

TY - JOUR

T1 - Developments in component therapy

T2 - novel components and new uses for familiar preparations.

AU - Wright-Kanuth, Michelle S.

AU - Smith, Linda A.

PY - 2002/3

Y1 - 2002/3

N2 - Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified. The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products. In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include: donor leukocyte infusions, dendritic cell vaccines, blood substitutes, novel platelet products and substitutes, intravenous immunoglobulin (IVIG), fresh frozen plasma and cryosupernatant in therapeutic plasma exchange. The variety of products and conditions reflect the ever-expanding role of immunohematology in the treatment of disease.

AB - Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified. The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products. In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include: donor leukocyte infusions, dendritic cell vaccines, blood substitutes, novel platelet products and substitutes, intravenous immunoglobulin (IVIG), fresh frozen plasma and cryosupernatant in therapeutic plasma exchange. The variety of products and conditions reflect the ever-expanding role of immunohematology in the treatment of disease.

UR - http://www.scopus.com/inward/record.url?scp=0038209600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038209600&partnerID=8YFLogxK

M3 - Article

C2 - 12776775

AN - SCOPUS:0038209600

VL - 15

SP - 116

EP - 124

JO - Journal of Medical Technology

JF - Journal of Medical Technology

SN - 0894-959X

IS - 2

ER -